Analyst Price Target is $13.25
▲ +301.52% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CorMedix in the last 3 months. The average price target is $13.25, with a high forecast of $19.00 and a low forecast of $10.00. The average price target represents a 301.52% upside from the last price of $3.30.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in CorMedix. This Buy consensus rating has held steady for over two years.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.